Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Metis Global Partners LLC

Metis Global Partners LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 61,011 shares of the biopharmaceutical company’s stock after selling 1,131 shares during the quarter. Metis Global Partners LLC’s holdings in Gilead Sciences were worth $5,636,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in GILD. AMF Tjanstepension AB raised its holdings in shares of Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock valued at $33,645,000 after purchasing an additional 51,390 shares in the last quarter. Swedbank AB raised its holdings in shares of Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after purchasing an additional 189,622 shares in the last quarter. Diversify Wealth Management LLC raised its holdings in shares of Gilead Sciences by 48.6% in the 3rd quarter. Diversify Wealth Management LLC now owns 6,115 shares of the biopharmaceutical company’s stock valued at $533,000 after purchasing an additional 2,000 shares in the last quarter. JFS Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 404.7% in the 3rd quarter. JFS Wealth Advisors LLC now owns 2,034 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 1,631 shares in the last quarter. Finally, Financial Advocates Investment Management raised its holdings in shares of Gilead Sciences by 4.6% in the 3rd quarter. Financial Advocates Investment Management now owns 15,111 shares of the biopharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 665 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 2.1 %

GILD stock opened at $114.31 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $114.77. The stock has a market capitalization of $142.46 billion, a PE ratio of 308.95, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a fifty day moving average of $97.42 and a 200-day moving average of $89.94.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.76%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GILD. Barclays raised their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Truist Financial raised their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Citigroup began coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price on the stock. Finally, Mizuho increased their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $102.08.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 293,356 shares of company stock worth $29,166,240 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.